# ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection

> **NCT02517515** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 650 (actual)

## Conditions studied

- Hepatitis C Virus (HCV)

## Interventions

- **DRUG:** ombitasvir/paritaprevir/ritonavir and dasabuvir
- **DRUG:** Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir

## Key facts

- **NCT ID:** NCT02517515
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2016-10
- **Final completion:** 2017-06
- **Target enrollment:** 650 (ACTUAL)
- **Last updated:** 2017-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02517515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02517515, "ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02517515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*